How would you counsel a patient concerned about receiving IMRT rather than IMPT for oropharyngeal cancer?

I would tell the patient there is absolutely no concern at all with IMRT, and it is a very well-established SOC. I am personally unclear about the OS benefit with IMPT, as it was pointed out, unexpected. It is unusual to see no difference in PFS and no tox difference, and yet there is an OS differen...

I would inform the patient that IMRT remains a well-established standard of care and is my first choice for definitive radiotherapy for oropharyngeal cancer. The reported survival difference in that trial was based on very few events and occurred in a study with significant crossover, as well as an ...

Treatment at a center of excellence with high volumes and/or a well-trained, experienced radiation oncologist and team is more important than proton or photon discussion, IMHO.

The question essentially contains the desired answer. Further, given limited media awareness, I think a true survival difference would be of interest to oncologists in general.

The question phrasing is interesting, as the conclusion of Frank et al., PMID 41391462 was that IMPT is "a standard..." and ...

I agree with @Dr. First Last and @Dr. First Last.

I agree with the responses provided by @Nancy Y. Lee and @C. Jillian Tsai. The most critical determinant of success in these complex patients is timely work-up, proper staging and treatment in a high-volume center with experienced head and neck radiation oncologists and a multidisciplinary team incl...

I would tell the patient that the investigators themselves did not have a clear biologic explanation for the survival difference they observed, since the cancer control rates were otherwise very similar between groups and the absolute number of treatment-related deaths was small: only 9 across both ...